華大基因(300676.SZ)：2021年度預盈14億元-16億元
格隆匯1月25日丨華大基因(300676.SZ)披露2021年度業績預吿，預計2021年度實現歸屬於上市公司股東的淨利潤14.00億元-16.00億元；預計2021年度實現歸屬於上市公司股東的扣除非經常性損益後的淨利潤12.70億元-15.20億元。報吿期內，公司持續加強技術研發與前瞻性產品佈局，並取得積極經營成效：
在生育健康方面，公司升級了安馨可新生兒遺傳病基因+代謝篩查產品，並開展了全國多中心項目；全面升級了耳聾疾病基因診斷臨牀解決方案；全面提升了無創產前基因檢測胎兒基因組疾病的性能；發佈了遺傳病檢測高效能解決方案，升級了全外顯子組檢測產品，推出並上市個體化用藥指導基因檢測(安覓方®快速版)產品，發佈CNV-seq智能化解讀雲平台。在目前人口結構變化的背景下，公司提前研判市場承接力，生育健康相關的多項產品均取得了較快增長。
在腫瘤防控方面，華常康®無創腸癌基因檢測全流程本地化解決方案上市，提升了公司在腫瘤檢測方面的核心競爭力；基於基因組及表觀組等多組學技術的各項重點癌種早篩產品研發項目進展積極。公司腫瘤個體化診療和用藥指導基因檢測產品在報吿期內取得高速增長，並不斷推進普惠民生大健康場景下的腫瘤防控服務。
在感染防控方面，基於宏基因組技術優勢加速入院轉化，新推出了基於並行計算加速的質控和比對算法，具有獨立知識產權的PMseqDatician病原專家分析系統；發佈了PMEasyDoctor病原組學大數據分析套件，進一步助力宏基因組學檢測技術落地醫院；PMseq®病原數據庫再次升級，擴大了檢測範圍。
在多組學大數據方面，公司在大羣體大隊列基因組研究及應用方面取得重要突破。報吿期內，公司中標了四川大學華西醫院十萬例罕見病患者全基因組測序計劃採購項目，截至報吿期末，該項目已正式啟動並有序推進中，有助於推動基因科技支持臨牀科研的發展，支撐全球生命科學研究進展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
